Submit your COVID-19 vaccine trial samples to CEPI's Centralised Labs Network
CEPI has established a Centralised Labs Network to enable the harmonisation of assessment of COVID-19 vaccine trial data (preclinical to Phase II testing).
Located across multiple regions globally, the seven network laboratories will use the same testing reagents and follow common protocols to measure the immunogenicity of multiple COVID-19 vaccine candidates.
The network is open for use to all COVID-19 vaccine developers (both CEPI-supported and non-CEPI-funded vaccine developers).
In order to monitor interest and adjust the testing capacity, we are requesting that all COVID-19 vaccine developers interested in using CEPI’s centralised laboratory network, please complete this short survey.
For any COVID-19 vaccine developer ready to submit their samples to the network, please complete the form below.